Search

Byline: J.-J. Yeh (), F.-Y. Liu (), W.-H. Hsu (), J.-J. Wang (), S.-T. Ho (), A. Kao () Abstract: The purpose of this study was to evaluate the markers' clinical usefulness for early prediction of recurrence, by serial and simultaneous measurements of serum cytokeratin fragment 19 (CYFRA 21-1), before and after surgery on patients with non-small cell lung cancers (NSCLC). The 48 patients enrolled in this study had adenocarcinoma of the lung (adenoCa) (including 24 patients with recurrence and 24 patients without recurrence 1 year after surgery) and 48 patients with squamous cell carcinoma of the lung (SCC) (including 24 cases with recurrence and 24 without recurrence 1 year after surgery). Serial serum levels of CYFRA 21-1 were measured before the operation and 1 week, 1 month, 3 months, 6 months, 9 months, and 12 months after surgery for the early detection of recurrence. The results revealed that (1) the mean serum values of CYFRA 21-1 were significantly higher beginning at 1 month after surgery in the 24 patients with recurrent adenoCa compared with the 24 patients without recurrent adenoCa, (2) mean serum values of CYFRA 21-1 were significantly higher beginning at 1 month after surgery in 24 patients with recurrent SCC when compared with 24 patients without recurrent SCC, and (3) mean serum values of CYFRA 21-1 were significantly higher beginning at 1 month after operation in the total 48 patients with recurrent NSCLC when compared with 48 patients without recurrent NSCLC. We conclude that CYFRA 21-1 is not a good marker for early prediction of NSCLC recurrence including adenoCa and SCC after surgery. Author Affiliation: () Department of Thoracic Medicine, Ping Tung Christian Hospital, and Mei Ho Institute of Technology, Ping Tung, Taiwan, TW () Department of Nuclear Medicine, Far Eastern Memorial Hospital, Taipei, Taiwan, TW () Division of Pulmonary/Critical Care Medicine, Department of Internal Medicine, China Medical College Hospital, Taichung, Taiwan, TW () Department of Medical Research, Chi-Mei Medical Center, Tainan, Taiwan, TW () School of Medicine, Nation al Defense Medical Center, Taipei, Taiwan, TW () Department of Medical Research, China Medical College Hospital, No. 2, Yuh-Der Road, Taic hung 404, Taiwan, TW Article History: Accepted Date: 10/09/2002

Byline: C.-H. Kao (1), J.-F. Hsieh (2), Y.-J. Ho (3), H.-J. Ding (4) Keywords: Key words: Cytokeratin fragment 19 (CYFRA 21-1)--Carcinoembryonic antigen--Lung adenocarcinoma. Abstract: Fifty patients with adenocarcinoma of the lung were enrolled in this study, including 20 patients with recurrence and 30 patients without recurrence 1 year after surgery. Serial serum levels of cytokeratin fragment 19 (CYFRA 21-1) and carcinoembryonic antigen (CEA) were measured before the operation and 1 week, 1 month, 3 months, 6 months, 9 months, and 12 months after surgery for the early detection of recurrence. The results revealed that the mean serum values of either CYFRA 21-1 or CEA were significantly higher until 9 and 12 months after surgery in the 20 patients with recurrent adenocarcinoma compared with the 30 patients without recurrent adenocarcinoma. We conclude that CYFRA 21-1 is not a better marker than CEA for early prediction of adenocarcinoma. We conclude that CYFRA 21-1 is not a better marker than CEA for early prediction of adenocarcinoma recurrence in lung. Author Affiliation: (1) Department of Nuclear Medicine, Taichung Veterans General Hospital, Taiwan, TW (2) Department of Nuclear Medicine, Chi-Mei Foundation Hospital, Taiwan, TW (3) Department of Radiology, Jen-Ai Hospital, Taiwan, TW (4) Department of Nuclear Medicine and School of Technology for Medical Sciences, Kaohsiung Medical College, Taiwan, TW Article note: Accepted for publication: 7 July 1999

Byline: Vivek. Mishra, Abanti. Saha, Debabrata. Bandyopadhyay, Anirban. Das Verrucous epidermal nevi are congenital, noninflammatory cutaneous hamartomas composed of keratinocytes. They follow the lines of Blaschko and show hyperkeratosis without [...]

* Context.--Basaloid squamous cell carcinoma (bSCC) is an uncommon variant of squamous cell carcinoma, which may overlap histologically with basal cell carcinoma with squamous metaplasia (BCCm). Objective.--To aid in the differentiation of these neoplasms using immunohistochemical staining because of the worse prognosis associated with bSCC. Design.--Using immunohistochemical techniques, we investigated BerEp4, cytokeratin 17 (CK17), and cytokeratin 14 (CK14) protein expression in 25 cases of bSCC (8 cutaneous [32%], 12 aerodigestive tract [48%], and 5 lymph node metastases [20%]) and 43 cases of BCCm (39 cutaneous [91%], and 4 metastases [9%]). An immunoreactivity score was assigned using the percentage of tumor cells staining and the pattern of expression. Interobserver agreement for 2 independent pathologists was assessed using a κ coefficient. Results.--The mean percentage of staining was significantly higher in BCCm, compared with bSCC (BerEp4, P = .006; CK17, P < .001; CK14, P < .001; unpaired t test), with 58% of BCCm cases (25 of 43) displaying diffuse staining for all markers, and nearly all (98%; 42 of 43) displaying diffuse staining for CK17 and CK14. In contrast, no bSCC cases (0%) displayed diffuse staining for all 3 markers, and only 8% (2 of 25) displayed diffuse staining for CK17 and CK14. High interobserver agreement was determined. Conclusions.--BerEp4 alone is unreliable for differentiation between BCCm and bSCC, and the addition of either CK14 or CK17 will augment the sensitivity and negative predictive value of BerEp4 staining in BCCm and bSCC diagnosis. (Arch Pathol Lab Med. 2013; 137:1591-1598; doi: 10.5858/arpa.2012-0424-OA), Basaloid malignancies of the skin include basaloid squamous cell carcinoma (bSCC) and basal cell carcinoma with squamous metaplasia (BCCm), 2 lesions with morphologic overlap but vastly different potential outcomes clinically. [...]